Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio del primo umano di KK2223 nei partecipanti con linfoma non hodgkin recidivante o refrattario

29 settembre 2026 aggiornato da: Kyowa Kirin, Inc.

Uno studio di fase 1, multicentrico, aperto, non randomizzato, dose-escalation e backfill di KK2223 nei partecipanti con linfoma non hodgkin recidivante o refrattario a cellule T.

The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of KK2223 in adult participants with relapsed or refractory peripheral T cell lymphoma (PTCL) or cutaneous T cell lymphoma (CTCL).

Panoramica dello studio

Stato

Reclutamento

Intervento / Trattamento

Descrizione dettagliata

This is a Phase 1, multicenter, open-label, non randomized study in participants with relapsed or refractory PTCL or CTCL. This study consists of Part 1 (dose-escalation) and Part 2 (backfill). The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of K2223 in r/r T-cell NHL (PTCL or CTCL)

Tipo di studio

Interventistico

Iscrizione (Stimato)

72

Fase

  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

      • Bergamo, Italia, 24127
        • Non ancora reclutamento
        • Azienda Ospedaliera Papa Giovanni XXIII - Ematologia
        • Investigatore principale:
          • Giuseppe Gritti
        • Contatto:
      • Bologna, Italia, 40138
        • Non ancora reclutamento
        • Azienda Ospedaliero Universitaria di Bologna IRCCS (Policlinico di Sant'Orsola) - Ematologia
        • Contatto:
        • Investigatore principale:
          • Luigi Zinzani Pier
      • Torino, Italia, 10126
        • Non ancora reclutamento
        • AOU Citta' della Salute e della Scienza di Torino Ospedale Molinette, Ematologia Universitaria
        • Contatto:
        • Investigatore principale:
          • Federica Cavallo
    • Torino
      • Candiolo, Torino, Italia, 10060
        • Non ancora reclutamento
        • Istituto di Candiolo, IRCCS - Oncologia Medica ed Ematologia
        • Investigatore principale:
          • Umberto Vitolo
        • Contatto:
      • Madrid, Spagna, 28027
        • Non ancora reclutamento
        • Clinica Universidad de Navarra - Hematología y Hemoterapia
        • Contatto:
        • Investigatore principale:
          • Migue Canales Albendea
    • Barcelona
      • Badalona, Barcelona, Spagna, 8036
        • Non ancora reclutamento
        • Hospital Clinic De Barcelona - Hematología
        • Investigatore principale:
          • Pablo Mozas
        • Contatto:
      • L'Hospitalet de Llobregat, Barcelona, Spagna, 8907
        • Non ancora reclutamento
        • Institut Català d'Oncologia (ICO) - ICO L'Hospitalet - Hematologia
        • Investigatore principale:
          • Eva Domingo Domenech
        • Contatto:
    • Navarre
      • Pamplona, Navarre, Spagna, 31008
        • Non ancora reclutamento
        • Clinica Universidad de Navarra - Hematología
        • Contatto:
        • Investigatore principale:
          • Miguel Canales Albendea
    • California
      • Duarte, California, Stati Uniti, 91010
        • Non ancora reclutamento
        • City of Hope
        • Investigatore principale:
          • Christina Poh
        • Contatto:
          • Christina Poh
          • Numero di telefono: 916-734-7131
          • Email: cpoh@coh.org
      • Orange, California, Stati Uniti, 92868
        • Non ancora reclutamento
        • University of California, Irvine Medical Center - Hematology/Oncology
        • Contatto:
        • Investigatore principale:
          • Lauren Pinter Brown
      • Stanford, California, Stati Uniti, 94305
        • Reclutamento
        • Stanford University School of Medicine
        • Investigatore principale:
          • Youn Kim
        • Contatto:
    • Florida
      • Tampa, Florida, Stati Uniti, 33612
        • Non ancora reclutamento
        • Moffit Cancer Center
        • Contatto:
        • Investigatore principale:
          • Yumeng Zhang
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30322
        • Non ancora reclutamento
        • Emory University Medical Center
        • Investigatore principale:
          • Pamela Allen
        • Contatto:
    • Iowa
      • Iowa City, Iowa, Stati Uniti, 52242
        • Non ancora reclutamento
        • University of Iowa Health
        • Investigatore principale:
          • Eric Mou
        • Contatto:
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02215
        • Non ancora reclutamento
        • Beth Israel Deaconess Medical Center - Research
        • Contatto:
        • Investigatore principale:
          • Salvia Jain
    • Missouri
      • St Louis, Missouri, Stati Uniti, 63110
        • Reclutamento
        • Washington University School of Medicine - Oncology Hospital - Public
        • Investigatore principale:
          • Neha Mehta Shah
        • Contatto:
    • New Jersey
      • Hackensack, New Jersey, Stati Uniti, 07601-2105
        • Non ancora reclutamento
        • Hackensack University Medical Center - John Theurer Cancer C - Lymphoma Division
        • Investigatore principale:
          • Tatyana Feldman
        • Contatto:
    • New York
      • New York, New York, Stati Uniti, 10021-6007
        • Reclutamento
        • Memorial Sloan Kettering Cancer Center
        • Investigatore principale:
          • Jasmine Zain
        • Contatto:
    • Ohio
      • Cleveland, Ohio, Stati Uniti, 44106
        • Non ancora reclutamento
        • University Hospitals Cleveland Medical Center
        • Contatto:
        • Investigatore principale:
          • Kevin Cooper
    • Oregon
      • Portland, Oregon, Stati Uniti, 97239
        • Non ancora reclutamento
        • Oregon Health & Science University
        • Contatto:
        • Investigatore principale:
          • Craig Okada
    • Pennsylvania
      • Philadelphia, Pennsylvania, Stati Uniti, 19104
        • Non ancora reclutamento
        • University of Pennsylvania - Abramson Cancer Center
        • Investigatore principale:
          • Stefan Barta
        • Contatto:
    • Texas
      • Houston, Texas, Stati Uniti, 77030
        • Reclutamento
        • The University of Texas - MD Anderson Cancer Center
        • Investigatore principale:
          • Ranjit Nair
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Adults (≥18 years) with confirmed T-cell lymphoma subtypes: PTCL (including nodal T-follicular helper cell lymphoma, ALCL, PTCL NOS) for Parts 1 and 2; CTCL (mycosis fungoides or Sézary syndrome, stages IIB-IV) for Parts 1 and 2, with specific disease involvement criteria in Part 2.
  • PTCL participants must have relapsed/refractory/intolerant to ≥1 systemic therapy; CD30+ PTCL must have prior brentuximab vedotin treatment or intolerance, and/or ALK-positive ALCL participants should have previously received crizotinib if indicated (crizotinib administration is applicable to US sites only). CTCL participants must have relapsed/refractory/intolerant to ≥2 systemic therapies.
  • Availability of tumor tissue (current or archival) is required.
  • Measurable disease required: nodal/extranodal lesions for PTCL and assessable skin disease for CTCL.
  • ECOG performance status 0-1; adequate neutrophils (≥1000/µL), platelets (≥75,000/µL), renal function (creatinine clearance ≥60 mL/min), liver function within defined limits, and total bilirubin ≤1.5× ULN (up to 3× ULN with Gilbert's syndrome).
  • Body weight 40 kg to ≤ 200 kg
  • Life expectancy ≥3 months.
  • Negative pregnancy test for females of childbearing potential; contraception required for females and males with partners of childbearing potential during and after treatment.
  • Restrictions on gamete donation and freezing during and after treatment.
  • Ability to provide informed consent and comply with study procedures. -

Exclusion Criteria:

  • Recent autologous or allogeneic transplant within 120 days before treatment; active GVHD or ongoing immunosuppression after allogeneic transplant; prior HSCT and with active VOD/SOS
  • Pregnant or breastfeeding females, or those intending pregnancy.
  • History of HIV, HBV, or HCV infections generally excluded, except for controlled or resolved cases as defined.
  • Uncontrolled infections requiring antibiotics, antivirals, or antifungals at screening through treatment start.
  • Significant medical history or complications within six months prior to enrollment, including advanced congestive heart failure (NYHA Class III or higher), recent unstable angina or myocardial infarction, autoimmune diseases requiring systemic immunosuppressive therapy, active or uncontrolled ocular diseases, Grade 3 or 4 peripheral neuropathy, or other poorly controlled conditions as judged by the investigator (e.g., uncontrolled hypertension, diabetes, or arrhythmias).
  • Use of other investigational drugs within 14 days or 5 half-lives before treatment.
  • Steroid use over 10 mg/day prednisone equivalent within 14 days prior, except limited corticosteroid use with specific tapering guidelines; topical steroids allowed under conditions for CTCL.
  • Major surgery, radiotherapy, chemotherapy, or other anti-cancer treatments within 14 days or 5 half-lives before treatment.
  • Prior mogamulizumab use within six months before treatment; associated rash must be ruled out if >6 months.
  • Known history of Grade ≥ 3 hypersensitivity to mogamulizumab.
  • Failure to recover from prior non-hematologic toxicities to Grade 0 or 1 (except alopecia and mild neuropathy).
  • Prolonged QT/QTc interval (e.g., QTcF >480 ms).
  • Active second primary malignancies except specified non-exclusionary cases.
  • CNS involvement.
  • Any condition that may impair compliance or study completion as judged by the Investigator.
  • Known hypersensitivity to any excipients in the drug formulation.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione sequenziale
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Part One (Dose Escalation)

In Part 1, safety and tolerability of KK2223 in relapsed/refractory PTCL or CTCL patients will be assessed using a BOIN dose-escalation design.

Intravenous infusion

Sperimentale: Part Two (Backfill)

Part 2 will collect additional data, with dose levels and cohort size based on Part 1 results, administering doses approved for tolerability. Backfill cohorts at cleared doses may open, prioritizing Part 1 enrollment.

Intravenous infusion

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Lasso di tempo: Through study completion, an average of 1.5 years

Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 (all 72 potentially treated subjects)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Lasso di tempo: Through study completion, an average of 1.5 years

Vital signs (mmHg in Systolic/Diastolic blood pressure)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Lasso di tempo: Through study completion, an average of 1.5 years

Pulse rate (beats/min)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Lasso di tempo: Through study completion, an average of 1.5 years

Respiratory Rate (breath/min)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Lasso di tempo: Through study completion, an average of 1.5 years

Temperature (°Celcius)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Lasso di tempo: Through study completion, an average of 1.5 years

ECG parameters (PR interval, QRS interval, QT interval, QTc interval)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Lasso di tempo: Through study completion, an average of 1.5 years

Number of participants with dose-limiting toxicities (DLTs) in Part 1 only (at most 27 participants) and assess maximum tolerated dose (MTD)

Through study completion, an average of 1.5 years

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Mean Blood Drug Concentration
Lasso di tempo: Through study completion, an average of 1.5 years

The mean drug concentration in the blood

Through study completion, an average of 1.5 years
To evaluate the immunogenicity of KK2223.
Lasso di tempo: Through study completion, an average of 1.5 years

Incidence of Anti drug antibodies (ADA) in blood

Through study completion, an average of 1.5 years
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Lasso di tempo: Through study completion, an average of 1.5 years

% in Overall Response Rate (ORR)

Through study completion, an average of 1.5 years
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Lasso di tempo: Through study completion, an average of 1.5 years

% in Compartment Response (if applicable)

Through study completion, an average of 1.5 years
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Lasso di tempo: Through study completion, an average of 1.5 years

Time unit (week/month) in Duration of Response (DOR)

Through study completion, an average of 1.5 years
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Lasso di tempo: Through study completion, an average of 1.5 years

Time unit (week/month) in Time To Next Treatment (TTNT) will be evaluated

Through study completion, an average of 1.5 years
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Lasso di tempo: Through study completion, an average of 1.5 years

Time unit (week/month) in Time To Response (TTR)

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Maximum Blood Concentration (Cmax)
Lasso di tempo: Through study completion, an average of 1.5 years

The maximum drug concentration

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Area Under the Concentration-time Curve (AUC)
Lasso di tempo: Through study completion, an average of 1.5 years

A measure of the overall drug exposure over time

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Time to Maximum Concentration (Tmax)
Lasso di tempo: Through study completion, an average of 1.5 years

The time taken to reach the maximum drug concentration

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Terminal Half-Life (Thalf)
Lasso di tempo: Through study completion, an average of 1.5 years

The time required for the drug concentration to decrease by 50%

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Clearance (CL)
Lasso di tempo: Through study completion, an average of 1.5 years

Rate of drug elimination from the body

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Volume of Distribution at Steady State (Vss)
Lasso di tempo: Through study completion, an average of 1.5 years

Theoretical volume of distribution at steady state and reflects the extent of drug istribution into tissues

Through study completion, an average of 1.5 years

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

2 settembre 2026

Completamento primario (Stimato)

1 marzo 2029

Completamento dello studio (Stimato)

1 settembre 2030

Date di iscrizione allo studio

Primo inviato

12 agosto 2025

Primo inviato che soddisfa i criteri di controllo qualità

17 settembre 2025

Primo Inserito (Effettivo)

25 settembre 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

30 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

29 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

The datasets generated and/or analyzed during the study sponsored by Kyowa Kirin will be available in the Vivli repository, https://vivli.org/ourmember/kyowa-kirin/ as long as conditions of data disclosure specified in the policy section of the Vivli website are satisfied.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi